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12, Léo Bühler13, Jurg Steiger4, Oriol Manuel2,14, Manuel Pascual2‡,
Dela GolshayanID
2‡*, and the Swiss Transplant Cohort Study (STCS)¶
1 Service of Pharmacy, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne,
Switzerland, 2 Transplantation Center, Lausanne University Hospital (CHUV) and University of Lausanne
(UNIL), Lausanne, Switzerland, 3 Nephrology and Transplantation Medicine, Cantonal Hospital St. Gallen, St
Gallen, Switzerland, 4 Clinic for Transplantation Immunology and Nephrology, University Hospital Basel,
Basel, Switzerland, 5 Division of Nephrology, Hypertension and Clinical Pharmacology, Inselspital Bern,
Bern, Switzerland, 6 Division of Nephrology and Division of Transplantation, Geneva University Hospitals,
Geneva, Switzerland, 7 Division of Nephrology, University Hospital Zurich, Zurich, Switzerland, 8 Basel
Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland, 9 Service
of Clinical Pathology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne,
Switzerland, 10 Division of Clinical Pathology, Department of Pathology and Immunology, Geneva University
Hospitals, Geneva, Switzerland, 11 Pathology Institute, University Hospital Basel, Basel, Switzerland,
12 Service of Immunology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL),
Lausanne, Switzerland, 13 Visceral and Transplant Surgery, Department of Surgery, Geneva University
Hospitals, Geneva, Switzerland, 14 Service of Infectious Diseases, Lausanne University Hospital (CHUV)
and University of Lausanne (UNIL), Lausanne, Switzerland
☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
¶ Membership of the Swiss Transplant Cohort Study (STCS) Group is listed in the Acknowledgments.
* dela.golshayan@chuv.ch
Abstract
Acute antibody-mediated rejection (AMR) remains a challenge after kidney transplantation
(KT). As there is no clear-cut treatment recommendation, accurate information on current
therapeutic strategies in real-life practice is needed. KT recipients from the multicenter
Swiss Transplant Cohort Study treated for acute AMR during the first post-transplant year
were included retrospectively. We aimed at describing the anti-rejection protocols used rou-
tinely, as well as patient and graft outcomes, with focus on infectious complications. Overall,
65/1669 (3.9%) KT recipients were treated for 75 episodes of acute AMR. In addition to cor-
ticosteroid boluses, most common therapies included plasmapheresis (56.0%), intravenous
immunoglobulins (IVIg) (38.7%), rituximab (25.3%), and antithymocyte globulin (22.7%). At
least one infectious complication occurred within 6 months from AMR treatment in 63.6% of
patients. Plasmapheresis increased the risk of overall (hazard ratio [HR]: 2.89; P-value =
0.002) and opportunistic infection (HR: 5.32; P-value = 0.033). IVIg exerted a protective
effect for bacterial infection (HR: 0.29; P-value = 0.053). The recovery of renal function was
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complete at 3 months after AMR treatment in 67% of episodes. One-year death-censored
graft survival was 90.9%. Four patients (6.2%) died during the first year (two due to severe
infection). In this nationwide cohort we found significant heterogeneity in therapeutic
approaches for acute AMR. Infectious complications were common, particularly among KT
recipients receiving plasmapheresis.
Introduction
Acute antibody-mediated rejection (AMR) is a potential cause of kidney allograft loss [1–3].
Despite significant advances on the recognition and diagnostic strategies of this clinical entity,
the efficacy and safety of the different therapeutic approaches of AMR are not fully established
[4]. In 2009, the Kidney Disease Improving Global Outcomes (KDIGO) clinical guidelines rec-
ommended a number of treatment alternatives, with or without corticosteroids (grade 2C rec-
ommendations), including plasmapheresis, intravenous immunoglobulins (IVIg), anti-CD20
monoclonal antibody (mAb), and lymphocyte-depleting antibodies [5]. These recommenda-
tions were recently updated by The Transplantation Society Working Group, and the standard
of care for acute active AMR remains plasmapheresis, IVIg (grade 2C) with corticosteroids
(expert opinion), and adjunctive therapy in specific settings (grade 2B) [6].
Historically alloantibody removal by plasmapheresis was the first strategy used, associated
or not with the immunomodulating effect of IVIg therapy [7–13]. This strategy was then rein-
forced by aiming to reduce the production of alloantibodies with rituximab, a B-cell-depleting
mAb, and bortezomib, a proteasome inhibitor leading to apoptosis of plasma cells [14–19].
More recently, the goal has been to inhibit the complement pathway by using eculizumab, a
humanized anti-C5 mAb [20–24]. Nevertheless, none of these strategies has been evaluated in
appropriately-powered controlled clinical trials [6, 13]. Beyond efficacy, few studies have sys-
tematically assessed the rate of adverse events (and in particular of infectious complications) in
patients after AMR treatment. In a recent meta-analysis, only 6 clinical trials of rituximab, bor-
tezomib and eculizumab reported the incidence of infectious diseases complications [13].
Because of a limited number of patients and the heterogeneity in methodology, a detailed epi-
demiology of infection and its associated risk factors were not reported in these studies.
In view of the lack of high level evidence to guide the optimal choice of acute AMR treat-
ment after kidney transplantation (KT) and the risks associated with the subsequent increase
in immunosuppression, we analyzed in a real-life nationwide transplant cohort the current




This study was performed within the prospective nationwide Swiss Transplant Cohort Study
(STCS, www.stcs.ch, ClinicalTrials.gov: NCT01204944), that was approved by the Ethics Com-
mittees of all participating centers (Swissethics BASEC project 2018–022394). Written
informed consent was given by all participants, enabling the use of patient- and graft-specific
data [25, 26]. This nested study was approved by the Scientific Committee of the STCS, which
granted permission to the investigators to use the data from the STCS. For the present study,
all kidney transplant recipients recruited in the STCS cohort from May 2008 to May 2014 with
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a treated acute AMR episode within the first post-transplant year were included. All biopsies
were recorded in the STCS database and scored according to Banff classification by each cen-
ter’s reference pathologist [27–29]. Referent nephrologists at each center were requested to ret-
rospectively confirm the diagnosis of acute AMR and we subsequently analyzed all treated
AMR episodes (i.e. requiring the administration of additional anti-rejection therapy). Of note,
mixed acute rejection (i.e. AMR together with T-cell-mediated rejection [TCMR]) were also
included. In patients diagnosed with >1 episode, each episode was separately analyzed. ABO
incompatible transplants were excluded.
Data collection
The STCS cohort and database have been described previously, and in a recent survey of infec-
tious complications within the STCS [25, 26, 30]. For the present study, a standardized case
report form was filled by referent nephrologists to collect additional specific data. Baseline
recipient data included age, gender, pre-transplant diabetes, underlying end-stage renal dis-
ease, number of transplantations and serostatus for relevant viruses. Transplant-related data
included type of donor, donor viral serostatus, complement-dependent cytotoxicity (CDC)
crossmatch, number of human leukocyte antigen (HLA) mismatches, type of induction ther-
apy, administration of anti-cytomegalovirus (CMV) and anti-Pneumocystis prophylaxis. The
following additional data were collected at the time of biopsy-proven rejection: body mass
index (BMI), serum creatinine (sCr) and 24-hour proteinuria, presence of DSA, maintenance
immunosuppressive and anti-rejection therapies [31]. Follow-up data included sCr levels and
24-hour proteinuria at 3 months after the AMR episode, occurrence of infectious events, one-
year patient and graft survival. Induction and maintenance immunosuppressive therapies, as
well as prophylaxis regimens, were prescribed as per local guidelines at each center.
Detection and characterization of donor-specific antibodies
In each center, pre-transplant sera were tested for the presence of anti-HLA antibodies using
multiplex technology solid phase assays [31]. Class I (i.e., HLA-A/B) and class II (i.e., HLA-DR/
DQ) anti-HLA antibodies were tested and compared with the HLA typing of the donor. DSA
were considered positive if mean fluorescence intensity (MFI) values were�1,000. Between
2008 and 2011, routine donor HLA typing was done without DQ specificity. Since 2012, all
donors were typed for class I and class II HLA molecules using PCR-SSP technology. Detection
of DSA against HLA-Cw and HLA-DP was not performed in the present cohort (2008–2014).
Treatment of AMR episodes
Two different extracorporeal techniques, plasmapheresis or immunoadsorption, were used
depending on availability at each center. Immunosuppressive drugs used as anti-rejection
therapy included IV methylprednisolone boluses (median total dose [MTD]: 1,500 mg), high-
dose IVIg (MTD: 2 g/Kg), rituximab (MTD: 375 mg/m2 body surface area), rabbit anti-thymo-
cyte globulin (ATG) (either Thymoglobulin1 [MTD: 3 mg/Kg] or ATG-Fresenius1 [MTD: 28
mg/Kg]), eculizumab (MTD: 1,800 mg), or bortezomib (MTD: 50 mg/m2 body surface area).
Of note, the substitutive doses of IVIg (0.4 g/Kg) given after plasmapheresis were not consid-
ered as anti-rejection therapy.
Infectious complications and study outcomes
All infections occurring within the first 6 months after the diagnosis of AMR were retrieved
from the STCS database and classified according to the definitions proposed by the Infectious
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Diseases Study Group of the STCS [25, 26]. For the present study, opportunistic infections were
defined as that due to intracellular bacteria (e.g. mycobacteria), herpesviruses (CMV, herpes sim-
plex virus [HSV] and varicella-zoster virus [VZV]), polyomaviruses (BK virus-associated
nephropathy), yeasts (invasive candidiasis and cryptococcosis), molds, P. jirovecii and parasites
(e.g. toxoplasmosis). Only episodes of symptomatic CMV disease were taken into account in the
risk factors analysis [32]. Infectious events were classified as proven (confirmed isolated patho-
gen with clinical signs and/or symptoms and treatment given) or probable (no pathogen identi-
fied but in the presence of suspicious clinical signs and/or symptoms leading to a treatment).
Baseline graft function was defined as the mean of the two sCr values prior to the acute
increase leading to the diagnosis of AMR. Efficacy of anti-rejection treatment was assessed by
comparing graft function at baseline and 3 months after the episode, and categorized as fol-
lows: full recovery (±10% of baseline value), no recovery (within ±10% of peak value at AMR
diagnosis and/or graft lost), and intermediate recovery (between baseline and peak values).
We also analyzed patient and death-censored graft survival at one year after the diagnosis and
treatment of AMR.
Statistical analysis
Quantitative data were shown as the mean ± standard deviation (SD) or median with interquar-
tile ranges (IQR). Qualitative variables were expressed as absolute and relative frequencies. Cate-
gorical variables were compared using the χ2 test. Student’s t-test or Mann-Whitney U test were
applied for continuous variables, as appropriate. Survival and time-to-event curves were plotted
by the Kaplan-Meier method and inter-group differences were compared with the log-rank test.
Risk factors predicting the occurrence of infection after AMR were assessed by uni- and multi-
variate Cox regression models. Two different approaches were explored: a “per-patient” analysis,
in which only the last AMR episode was taken as reference in patients with>1 episode (i.e.
observation period encompassed the entire 6-month interval following the last rejection episode,
unless graft loss or death occurred earlier); alternatively, we performed a “per-episode” analysis,
in which follow-up was censored at the time of the second/subsequent AMR episode (i.e. obser-
vation period could be shorter than 6 months if two consecutive episodes occurred<6 months
apart). Associations were expressed as hazard ratios (HRs) with 95% confidence interval (CI). All
significance tests were two-tailed. Statistical analysis was performed using SPSS 20.0 (IBM Corp.,
Armonk, NY) and Prism 6.0 (GraphPad Software Inc., La Jolla, CA).
Results
Patient characteristics
Among 1,669 STCS patients who underwent KT between May 2008 and May 2014, we identi-
fied 65 recipients (3.9% [95% CI: 3.0–4.8]) with at least one treated episode of acute AMR
within the first post-transplant year. Seven patients experienced >1 episode (total of 75 AMR
episodes), and one patient received two kidney transplants during the study period (total of 66
KT procedures). Two recipients with combined transplantations were included (kidney-liver
and kidney-pancreas). Demographics and clinical characteristics of the study population are
summarized in Table 1. All patients had a negative pre-transplant T-cell CDC crossmatch,
whereas 7.6% (5/66) had a positive pre-transplant B-cell CDC crossmatch. Pre-transplant HLA
DSA were detected in 66.7% (44/66) recipients at the time of transplantation. The distribution
of the number of DSA (per anti-HLA specificity) in 44 recipients was as follows: 1 DSA in
59.1% (26/44) of recipients, 2 DSA in 18.2% (8/44), 3 DSA in 13.6% (6/44) and�4 DSA in
9.1% (4/44). Induction and maintenance immunosuppression as well as prophylaxis regimens
are detailed in Table 2.
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Table 1. Demographics and clinical characteristics of the study population (n = 66 kidney transplant procedures
performed in 65 patients).
Variable
Recipient age at transplantation, years [mean ± SD] 46.1 ± 18.5
Gender of recipient (male) [n (%)] 37 (56.1)
Pre-transplant diabetes [n (%)] 9 (13.6)
BMI at the time of rejection, Kg/m2 [mean ± SD] 24.6 ± 4.8
BMI at the time of rejection, categorized [n (%)]
Underweight (<18.5 Kg/m2) 5 (7.6)
Normal weight (18.5–25.0 Kg/m2) 32 (48.5)
Overweigh (25.0–30.0 Kg/m2) 21 (31.8)
Obesity (>30.0 Kg/m2) 8 (12.1)




Underlying end-stage renal disease [n (%)]
Glomerulonephritis 17 (25.8)
Polycystic kidney disease 14 (21.2)
Diabetic nephropathy 4 (6.1)
Hypertensive nephroangiosclerosis 3 (4.5)
Chronic interstitial nephropathy 3 (4.5)
Reflux nephropathy 3 (4.5)
Congenital nephropathy 2 (3.0)
Unknown 5 (7.6)
Other 15 (22.7)





Positive EBV serostatus (anti-EBNA) [n (%)] 65 (98.5)
Positive HBV serostatus (anti-HBc) [n (%)]a 4 (6.6)
Positive HCV serostatus [n (%)] 4 (6.1)
Positive HIV serostatus [n (%)] 2 (3.0)
Type of donor [n (%)]
DBD donor 47 (71.2)
Living related donor 13 (19.7)
Living unrelated donor 5 (7.6)
DCD donor 1 (1.5)
Number of HLA mismatches [median (IQR)] 4 (3–5)
DSA at transplantation [n (%)]b 44 (66.7)
Latest PRA value �10% [n (%)]b 13 (23.2)
Delayed graft function [n (%)]c 10 (15.2)
BMI: body mass index; CMV: cytomegalovirus; D: donor; DBD: donation after brain death; DCD: donation after
circulatory death; DSA: donor-specific antibody; EBV: Epstein-Barr virus; EBNA: EBV nuclear antigen; HLA: human
leukocyte antigen; HBsAg: hepatitis B virus surface antigen; HCV: hepatitis C virus; HIV: human immunodeficiency
virus; IQR: interquartile range; PRA: panel-reactive antibody; R: recipient; SD: standard deviation.
a Data on HBV serostatus not available for 5 patients.
b Closest value to transplantation; data on PRA not available for 10 patients.
c Defined as need for dialysis or no decrease in sCr levels in the first week after transplantation.
https://doi.org/10.1371/journal.pone.0250829.t001
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Acute AMR episodes and anti-rejection therapies
Most (54.7% [41/75]) acute AMR episodes occurred within the first 4 weeks post-transplanta-
tion and 68.0% (51/75) within the first 3 months (Fig 1). The median interval from transplanta-
tion to the first episode was 14.0 days (IQR: 7.0–93.0). Primary graft non-function was reported
in one patient with pre-existing DSA. Of note, of the 75 episodes of acute AMR, 21 biopsies
(28%) showed also some signs of T-cell mediated rejection (TCMR). However, all patients had
the clinical (graft dysfunction, DSA) and histological features of acute active AMR (glomerulitis,
peritubular capillaritis, C4d positivity, and for some also signs of endothelitis).
The combination of two different anti-rejection therapies was used in most episodes (44.0%
[33/75]), followed by three therapies in 21.3% (16/75), four in 12.0% (9/75) and 5 in 5.3% (4/
75). Monotherapy with methylprednisolone boluses was used in 17.3% of cases [13/75]. In
addition to methylprednisolone boluses, the most common treatment modalities were plasma-
pheresis/immunoadsorption (<5 sessions: 45%, with the majority in this group (13/19) having
Table 2. Immunosuppression and prophylaxis regimens (n = 66 kidney transplant procedures performed in 65
patients).
Variable
Induction therapy [n (%)]a






Maintenance immunosuppression [n (%)]b
Tacrolimus 54 (81.1)
Serum trough level, ng/mL [mean ± SD] 8.8 ± 4.3
Cyclosporine 11 (16.7)
Serum trough level, ng/mL [mean ± SD] 202.7 ± 95.8
Prednisone/methylprednisolone 65 (98.5)
Prednisone dose, mg/day (median [IQR]) 25 (10–40)
Methylprednisolone dose, mg/day (median [IQR]) 125 (125–125)
Mycophenolate mofetil 50 (75.8)
Dose, g/day (median [IQR]) 2 (1–2)
Enteric-coated mycophenolic acid 12 (18.2)
Dose, mg/day (median [IQR]) 1,440 (720–1,440)
Azathioprine 4 (4.5)
Dose, mg/day (median [IQR]) 75 (75–75)
Antiviral prophylaxis for CMV [n (%)]c 37 (56.1)
Duration of prophylaxis, days [median (IQR)] 120.0 (85–181)
Anti-Pneumocystis prophylaxis [n(%)]d 65 (98.5)
Duration of prophylaxis, days [median (IQR)] 193 (158–227)
CMV: cytomegalovirus; IQR: interquartile range.
a The sum of percentages exceeds 100% because some patients received more than one induction therapy.
b At the time of rejection.
c Defined as the initiation of IV ganciclovir or oral valganciclovir within the first 2 post-transplant weeks.
d Defined as the initiation of trimethoprim-sulfamethoxazole, atovaquone, dapsone, or pentamidine initiated during
the first 3 months post-transplant and administered for�7 days.
https://doi.org/10.1371/journal.pone.0250829.t002
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had 5 sessions, 3/19 patients with 4 sessions, 3/19 only 2 sessions; 6–10 sessions: 38%; >10 ses-
sions: 17%) and IVIg, alone or in combination, followed by rituximab and ATG (Fig 2). Eculi-
zumab and bortezomib were rarely used. Overall, there were up to 20 different combination
regimens. The most common double therapy consisted of plasmapheresis (or immunoadsorp-
tion) with methylprednisolone boluses, and the most common triple therapy included plasma-
pheresis (or immunoadsorption), methylprednisolone and IVIg. One patient with pre-existing
Fig 1. Temporal distribution of episodes of acute AMR in the study cohort. AMR: antibody-mediated rejection.
https://doi.org/10.1371/journal.pone.0250829.g001
Fig 2. Description of therapeutic approaches in 75 episodes of acute AMR according to individual agents or
therapies used. AMR: antibody-mediated rejection; ATG: antithymocyte globulin (different formulations
[ATG-Fresenius1 or Thymoglobulin1]); IA: immunoadsorption; IVIg: intravenous immunoglobulins; PPh:
plasmapheresis.
https://doi.org/10.1371/journal.pone.0250829.g002
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DSA underwent splenectomy after multiple sessions of immunoadsorption and plasmaphere-
sis, one dose of rituximab and four doses of bortezomib.
Infectious complications
Overall, 63.6% (42/66) of recipients developed 96 episodes of infection within the first 6 months
following the diagnosis of acute AMR (incidence rate: 0.77 episodes/100 patient-days). The dis-
tribution of clinical syndromes and causative agents is detailed in Table 3. Most infections were
bacterial (42.7% [41/96]). Eighteen episodes of opportunistic infections occurred in 18.2% (12/
66) of patients and included BK polyomavirus-associated nephropathy (33.3% [6/18]), CMV
disease (27.8% [5/18]), invasive pulmonary aspergillosis (11.1% [2/18]); and Pneumocystis jiro-
vecii pneumonia (PCP), Candida esophagitis, VZV encephalitis, herpes zoster and mucocutane-
ous HSV infection (5.5% [1/18], each). Regarding CMV infection, 16.7% [3/18] of episodes
occurred in D+/R- recipients (all of them after discontinuation of valganciclovir prophylaxis).
The patient who developed VZV encephalitis was treated for severe AMR within the previous
month with multiple immunoadsorption and plasmapheresis sessions, methylprednisolone
boluses (cumulative dose of 1,250 mg), one dose of rituximab and four doses of bortezomib.
Table 4 shows the results of the multivariate analysis for predicting the occurrence of over-
all infections in the “per-patient” analysis, in which BMI at the time of rejection (HR [per uni-
tary increment]: 1.10; 95% CI: 1.03–1.17; P-value = 0.004) and plasmapheresis (HR: 2.89; 95%
CI: 1.46–5.74; P-value = 0.002) were risk factors. Accordingly, patients receiving plasmaphere-
sis (either as single therapy or in combination regimens) had higher cumulative incidence of
overall infection (Fig 3A). These results remain essentially unchanged in the “per-episode”
analysis (S1 Table in S1 File). When bacterial infection was specifically analyzed, induction
with rituximab (HR: 6.57; 95% CI: 2.09–20.71; P-value = 0.001) and BMI at the time of rejec-
tion (HR [per unitary increment]: 1.10; 95% CI: 1.00–1.21; P-value = 0.038) were risk factors,
whereas there was a protective effect with IVIg anti-rejection therapy (HR: 0.29; 95% CI: 0.08–
1.02; P-value = 0.053) (Table 5). The cumulative incidence of bacterial infection was signifi-
cantly lower in patients treated with IVIg-containing regimens (Fig 3B). Rituximab induction
and plasmapheresis remained as risk factors for bacterial infection in the multivariate model
based on the “per-episode” analysis. Regarding opportunistic infection, plasmapheresis was
the only risk factor found in the “per-patient” analysis (S2 Table in S1 File). When the model
was constructed on a “per-episode” basis, plasmapheresis (HR: 5.32; 95% CI: 1.15–27.70; P-
value = 0.033) also was identified as independent risk factor, and the administration of CMV
antiviral prophylaxis (HR: 0.25; 95% CI: 0.08–0.81; P-value = 0.022) was protective (Table 6).
Allograft and patient outcomes
At month 3 after AMR, full recovery of renal graft function was achieved in 66.7% (50/75) of
episodes, intermediate recovery occurred in 18.7% (14/75), whereas no recovery was observed
in 14.7% (11/75).
At one year after acute AMR, patient survival was 93.8% (Fig 4A). Two patients died due to
severe infectious complications. The first patient received corticosteroids, multiple plasmaphe-
resis sessions, IVIg and one dose of rituximab following the diagnosis of AMR at day 7 post-
transplantation. He successively experienced CMV disease (at day 17) and norovirus infection
(at day 49, which led to severe acute tubular necrosis and graft loss). The patient died at month
3 due to multiple organ failure in the context of PCP (despite trimethoprim-sulfamethoxazole
prophylaxis). The second patient experienced three different episodes of AMR (at days 7, 35
and 102). Anti-rejection therapies included methylprednisolone boluses, multiple plasmaphe-
resis sessions, ATG, IVIg and two doses of rituximab. After developing different complications
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(including Clostridioides difficile infection, Klebsiella pneumoniae bacteremia and BK virus-
associated nephropathy), he died due to invasive pulmonary aspergillosis 6 months after trans-
plantation. The causes of death for the other 2 patients were acute coronary syndrome (at
month 5 post-transplantation), and gastric cancer (diagnosed at month 6, presumably pre-
existing at the time of transplantation).
Death-censored graft survival was 89.4% (Fig 4B) at one year after the treatment of acute
AMR. The causes of graft loss were chronic AMR (4 cases), primary graft non-function, acute
tubular necrosis in the setting of norovirus infection, and hemorrhagic shock due to gastroin-
testinal bleeding secondary to duodenal ulcers.
Table 3. Clinical syndromes and causative agents of the episodes of infection occurring within the first 6 months
after the diagnosis of acute AMR (n = 96).
Clinical syndrome n (%)
Bacterial infection 41 (42.7)
Urinary tract infection 20
Surgical site infection 2
Respiratory tract infection 4
Gastrointestinal tract infection 3
Skin and skin structures infection 2
Bloodstream infection 10
Urinary source 7
Catheter-related or primary 2
Intra-abdominal source 1
Probable bacterial infectiona 13 (13.5)
Respiratory tract infection 7
Gastrointestinal tract infection 3
Other 3
CMV infection 18 (18.8)
CMV asymptomatic infectionb 13
CMV disease 5
Non-CMV viral infection 14 (14.6)
BK polyomavirus-associated nephropathy 6
Biopsy-proven 3
Probable 3
Respiratory tract infection 3
Gastrointestinal tract infection 2
Mucocutaneous HSV infection 1
Cutaneous zoster 1
VZV encephalitis 1
Fungal infection 10 (10.4)
Mucocutaneous candidiasis 4
Intra-abdominal candidiasis 2
Invasive pulmonary aspergillosis 2
Candida esophagitis 1
Pneumocystis jirovecii pneumonia 1
AMR: antibody-mediated rejection; CMV: cytomegalovirus; HSV: herpes simplex virus; VZV: varicella-zoster virus.
a No pathogen identified.
b Only treated episodes were considered.
https://doi.org/10.1371/journal.pone.0250829.t003
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Discussion
In this large nationwide cohort of KT recipients, 3.9% of patients experienced an acute AMR
episode that was managed using a large variety of therapeutic approaches within the first year
post-transplantation. As the pathogenesis and diagnostic criteria of acute AMR have been
refined over the past fifteen years, we did not expect such heterogeneity in the therapeutic
practices in this prospective contemporary cohort. Our observation however reflects the lack
of validated recommendations regarding the treatment of AMR after kidney transplantation.
Despite satisfactory overall patient and allograft outcomes, infectious complications (including
episodes of severe and life-threatening opportunistic infections) were however common, par-
ticularly bacterial infections (Table 3). We found a differential impact of the anti-rejection
strategies used on the associated risk of infection, giving support for the individualization of
prophylaxis and monitoring regimens in this challenging KT population with acute AMR.
In this cohort, almost two thirds of the patients developed infectious complications within
6 months following acute AMR. We could compare these data to a recent study by Van Delden
et al. that investigated the epidemiology of infectious events within the first year after trans-
plantation in the whole STCS database during the same study period between 2008 to 2014
[26]. Regarding the STCS overall kidney cohort, up to 53% of recipients (vs. 63.6% in our sub-
cohort treated for acute AMR) developed at least one episode of infection at 1-year post
Table 4. Univariate and multivariate analyses of risk factors predicting the occurrence of overall infection within the first 6 months after the diagnosis of acute





P-value Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Age at transplantation, years [mean ± SD] 48.4 ± 17.3 42.5 ± 20.1 0.208
Gender (male) [n (%)] 21 (52.5) 16 (61.5) 0.470
Pre-transplant diabetes [n (%)] 7 (17.5) 2 (7.7) 0.465
BMI at the time of rejection, Kg/m2 [mean ± SD] 26.0 ± 4.8 22.5 ± 3.9 0.002 1.09a 1.03–1.16 0.005 1.10a 1.03–1.17 0.004
Previous kidney transplantation [n (%)] 19 (47.5) 12 (46.2) 0.915
Number of HLA mismatches [median (IQR)] 4 (3–5) 4 (4–5) 0.482
D+/R- CMV serostatus [n (%)] 7 (17.5) 4 (15.4) 1.000
Living donor [n (%)] 7 (17.5) 11 (42.3) 0.027 0.46 0.19–1.00 0.052 - - -
Antithymocyte globulin as induction therapy [n (%)] 22 (55.0) 14 (53.8) 0.927
Rituximab as induction therapy [n (%)] 5 (12.5) 0 (0.0) 0.148
Antiviral prophylaxis for CMV [n (%)] 21 (52.5) 16 (61.5) 0.470
Delayed graft function [n (%)] 6 (15.0) 3 (11.5) 1.000
More than one episode of acute AMR [n (%)] 3 (7.5) 4 (15.4) 0.420
Methylprednisolone boluses as anti-rejection therapy [n (%)] 33 (82.5) 25 (96.2) 0.134
Plasmapheresis as anti-rejection therapy [n (%)] 28 (70.0) 8 (30.8) 0.002 2.76 1.39–5.46 0.003 2.89 1.46–5.74 0.002
Immunoadsorption as anti-rejection therapy [n (%)] 3 (7.5) 3 (11.5) 0.673
IVIg as anti-rejection therapy [n (%)] 12 (30.0) 11 (42.3) 0.305
Antithymocyte globulin as anti-rejection therapy [n (%)] 9 (22.5) 6 (23.1) 0.956
Rituximab as anti-rejection therapy [n (%)] 10 (25.0) 8 (30.8) 0.607
Eculizumab as anti-rejection therapy [n (%)] 2 (5.0) 1 (3.8) 1.000
Bortezomib as anti-rejection therapy [n (%)] 1 (2.5) 1 (3.8) 1.000
AMR: antibody-mediated rejection; BMI: body mass index; CI: confidence interval; CMV: cytomegalovirus; HLA: human leukocyte antigen; HR: hazard ratio; IVIg:
intravenous immunoglobulins.
a Hazard ratio per unitary increment.
https://doi.org/10.1371/journal.pone.0250829.t004
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transplantation. Overall, in a total of 1612 KT recipients 852 patients developed 1964 episodes
of clinically relevant infections during the first year after transplantation, among which 66%
were bacterial (1299/1964), 28% viral (551/1964), 5% fungal (104/1964) and 0.6% (10/1964)
parasitic infections. E.coli and Enterococcus sp were the most common bacterial pathogens
with 616/1964 (31.3%) and 217/1964 (11%) of all episodes of infection, respectively, mainly
responsible for urinary tract infections. Among viral pathogens, HSV and CMV accounted for
130/1964 (6.6%) and 125/1964 (6.4%) of all episodes of infection, respectively. Infection due to
Candida albicans was the most common fungal infectious complication in all KT recipients
(42/1964, 2.1%). In comparison, while the majority of infections were also due to bacterial
pathogens (41/96 episodes, 42.7%) in our patients that were treated for acute AMR, we
observed more episodes of opportunistic infections (18.2%), in particular CMV infection, BK
polyomavirus-associated nephropathy and invasive pulmonary aspergillosis.
CMV infection represented 18.8% of all episodes, including 5.2% of CMV disease. Of note, a
recent case-control study showed that AMR and/or therapy for AMR appears to be a risk factor
for CMV infection [33], so that individualized antiviral strategies (i.e. antiviral prophylaxis or rig-
orously performed preemptive therapy) are important and should be applied in these patients.
Most of our patients (56%) received anti-CMV prophylaxis, and the remaining had close monitor-
ing for CMV DNAemia, which may explain the relatively low incidence of CMV disease observed.
Besides CMV infection, our data highlight the risk of other severe opportunistic infections associ-
ated with the treatment of AMR, such as PCP pneumonia and VZV encephalitis that could be pre-
vented by appropriate prophylaxis. In our study, infection-attributable mortality at one year post-
transplantation was up to 3.1% (with both cases developing severe opportunistic infections follow-
ing multiple anti-rejection therapies), as compared to 0.74% in the whole STCS KT cohort [26].
Despite the large variability in therapeutic modalities used, the data granularity provided by
the STCS offered the opportunity to explore some effects of anti-rejection regimens on the sus-
ceptibility to infection. We found that the use of plasmapheresis (whatever other therapy it was
combined with) significantly increased the risk of overall infection, both in the “per-patient”
and “per-episode” analyses. Chung et al. also reported that KT recipients who underwent pre-
transplant plasmapheresis associated with rituximab induction had higher cumulative
Fig 3. Cumulative incidence of infection within the first 6 months after the diagnosis of acute AMR in the “per-
patient” analysis. (a) overall infection according to the use of plasmapheresis as anti-rejection therapy (log-rank test
P-value = 0.002); (b) bacterial infection according to the use of IVIg as anti-rejection therapy (log-rank test P-
value = 0.035). The last episode was taken as reference in patients with more than one rejection episode. AMR:
antibody-mediated rejection; IVIg: intravenous immunoglobulins.
https://doi.org/10.1371/journal.pone.0250829.g003
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incidence of infection than those without plasmapheresis [34]. It can be hypothesized that plas-
mapheresis has a deleterious effect on humoral immunity by decreasing serum immunoglobu-
lin levels and complement proteins, thereby impairing opsonophagocytosis and antibody
neutralizing activity against pathogens. Accordingly, IVIg administration as anti-rejection
therapy (i.e. administered at much higher doses than substitutive doses given after plasmaphe-
resis) exerted a protective effect for bacterial infection. The increased susceptibility to bacterial
pathogens among patients receiving induction therapy with rituximab may also support this
mechanism, since anti-CD20 agents deplete the B-cell compartment, which can be associated
with hypogammaglobulinemia [35]. Infection was also the most common serious adverse
event in a recent randomized study involving 38 patients comparing rituximab to placebo for
the therapy of AMR (in addition to plasmapheresis, IVIg, and steroids), with opportunistic
infections (such as CMV or nocardiosis) also being overrepresented in the rituximab group
[17]. Of note, one out of three patients treated with bortezomib was diagnosed with VZV
encephalitis, a life-threatening complication. Herpes zoster was the most common infection
observed after the introduction of first-generation proteasome inhibitors for hematological
malignancies [36] and, therefore, antiviral prophylaxis with acyclovir or valacyclovir is recom-
mended for VZV-seropositive patients with multiple myeloma during induction therapy with
bortezomib and for at least 4 weeks after its discontinuation [37]. Such recommendation could
also be extended to the KT population, potentially using a drug with large anti-herpes effect
such as valganciclovir [38].
Table 5. Univariate and multivariate analyses of risk factors predicting the occurrence of bacterial infection within the first 6 months after the diagnosis of acute







P-value Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Age at transplantation, years [mean ± SD] 47.5 ± 17.7 45.5 ± 18.9 0.683
Gender (male) [n (%)] 8 (40.0) 29 (63.0) 0.083
Pre-transplant diabetes [n (%)] 4 (20.0) 5 (10.9) 0.437
BMI at the time of rejection, Kg/m2 [mean ± SD] 26.5 ± 5.2 23.8 ± 4.4 0.037 1.11a 1.01–1.21 0.024 1.10a 1.00–1.21 0.038
Previous kidney transplantation [n (%)] 6 (30.0) 25 (54.3) 0.069
Number of HLA mismatches [median (IQR)] 4 (3–5) 4 (3.8–5) 0.977
Living donor [n (%)] 5 (25.0) 13 (28.3) 0.785
Antithymocyte globulin as induction therapy [n (%)] 10 (50.0) 26 (56.5) 0.625
Rituximab as induction therapy [n (%)] 4 (20.0) 1 (2.2) 0.027 5.40 1.77–16.49 0.003 6.57 2.09–20.71 0.001
Delayed graft function [n (%)] 3 (15.0) 6 (13.0) 1.000
More than one episode of acute AMR [n (%)] 2 (10.0) 5 (10.9) 1.000
Methylprednisolone boluses as anti-rejection therapy [n (%)] 16 (80.0) 42 (91.3) 0.232
Plasmapheresis as anti-rejection therapy [n (%)] 15 (75.0) 21 (45.7) 0.028 3.04 1.10–8.39 0.031 - - -
Immunoadsorption as anti-rejection therapy [n (%)] 1 (5.0) 5 (10.9) 0.659
IVIg as anti-rejection therapy [n (%)] 3 (15.0) 20 (43.5) 0.026 0.29 0.09–0.99 0.048 0.29 0.08–1.02 0.053
Antithymocyte globulin as anti-rejection therapy [n (%)] 6 (30.0) 9 (19.6) 0.358
Rituximab as anti-rejection therapy [n (%)] 5 (25.0) 13 (28.3) 0.785
Eculizumab as anti-rejection therapy [n (%)] 1 (5.0) 2 (4.3) 1.000
Bortezomib as anti-rejection therapy [n (%)] 0 (0.0) 2 (4.3) 1.000
AMR: antibody-mediated rejection; BMI: body mass index; CI: confidence interval; CMV: cytomegalovirus; HLA: human leukocyte antigen; HR: hazard ratio; IVIg:
intravenous immunoglobulins.
a Hazard ratio per unitary increment.
https://doi.org/10.1371/journal.pone.0250829.t005
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In addition to the detailed data on AMR treatment-associated infectious complications, the
present study extends previous observations regarding the relatively good prognosis of early
acute AMR if diagnosed and treated appropriately and rapidly [12, 39]. The death-censored
graft survival observed in our population was close to that recently reported in a larger cohort
of KT recipients with AMR and pre-existing DSA [39]. These findings support the possibility
of transplanting kidneys into sensitized recipients, using an appropriate induction therapy and
a close follow-up strategy aimed at infection prophylaxis and early detection of acute AMR.
However, the one-year follow-up of our study may be too short to properly capture medium-
and long-term patient and graft outcomes associated with AMR and its treatment. Our data
derive from the real-life setting of an ongoing nationwide cohort, emphasizing the broad het-
erogeneity in single-agent or combination immunosuppressive regimens used to treat acute
AMR. Despite lack of strong supporting evidence, a recent systematic review has shown that
plasmapheresis and IVIg have become the standard of care for acute AMR due to favorable
clinical outcomes reported in most centers [13]. However, the optimal dose of IVIg (median
Table 6. Univariate and multivariate analyses of risk factors predicting the occurrence of opportunistic infection within the first 6 months after the diagnosis of
acute AMR in the “per-episode” analysis (i.e. follow-up was censored at the time of diagnosis of the second or consecutive episodes in patients with more than one
rejection episode).
OI (n = 13) No OI (n = 62) P-value Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Age at the time of rejection, years [mean ± SD] 48.2 ± 18.6 47.5 ± 18.5 0.907
Gender (male) [n (%)] 6 (46.2) 26 (41.9) 0.780
Pre-transplant diabetes [n (%)] 2 (15.4) 7 (11.3) 0.650
BMI at the time of rejection, Kg/m2 [mean ± SD] 25.8 ± 4.9 24.2 ± 4.5 0.259
Previous kidney transplantation [n (%)] 6 (46.2) 30 (48.4) 0.883
DSA at transplantation [n (%)]a 10 (76.9) 41 (73.2) 1.000
DSA at the time of rejection [n (%)]b 12 (100.0) 44 (93.6) 1.000
D+/R- CMV serostatus [n (%)] 0 (0.0) 13 (21.0) 0.108
Living donor [n (%)] 0 (0.0) 20 (32.3) 0.015 0.192 0.03–1.48 0.113
Antithymocyte globulin as induction therapy [n (%)] 6 (46.2) 36 (58.1) 0.432
Rituximab as induction therapy [n (%)] 2 (15.4) 3 (4.8) 0.205
Antiviral prophylaxis for CMV [n (%)]c 4 (30.8) 40 (64.5) 0.025 0.28 0.09–0.91 0.034 0.25 0.08–0.81 0.022
Antiviral prophylaxis for CMV at the time of acute AMR [n (%)] 3 (8.8) 10 (24.4) 0.076
Delayed graft function [n (%)] 1 (7.7) 10 (16.1) 0.677
Previous episode of acute AMR [n (%)] 2 (15.4) 7 (11.3) 0.650
Methylprednisolone boluses as anti-rejection therapy [n (%)] 10 (76.9) 55 (88.7) 0.364
Plasmapheresis as anti-rejection therapy [n (%)] 11 (84.6) 29 (46.8) 0.013 5.66 1.25–25.55 0.024 5.32 1.15–27.70 0.033
Immunoadsorption as anti-rejection therapy [n (%)] 1 (7.7) 5 (8.1) 1.000
IVIg as anti-rejection therapy [n (%)] 5 (38.5) 24 (38.7) 0.987
Antithymocyte globulin as anti-rejection therapy [n (%)] 2 (15.4) 15 (24.2) 0.720
Rituximab as anti-rejection therapy [n (%)] 4 (30.8) 15 (24.2) 0.727
Eculizumab as anti-rejection therapy [n (%)] 0 (0.0) 3 (4.8) 1.000
Bortezomib as anti-rejection therapy [n (%)] 2 (15.4) 1 (1.6) 0.076 7.64 1.68–34.81 0.009 4.80 0.99–23.26 0.051
AMR: antibody-mediated rejection; BMI: body mass index; CI: confidence interval; CMV: cytomegalovirus; DSA: donor-specific antibody; HR: hazard ratio; IVIg:
intravenous immunoglobulins; OI: opportunistic infection.
a Data on pre-transplant DSA not available for 6 patients.
b Data on DSA at the time of rejection not available for 16 patients.
c Defined as the initiation of ganciclovir or valganciclovir within the first 2 weeks after transplantation.
https://doi.org/10.1371/journal.pone.0250829.t006
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dose of 2 g/Kg in our study) and the number of plasmapheresis sessions (about half of our
patients received more than 5 sessions) remain to be better defined, especially in view of the
increased infection risk we observed [40].
Our study has several limitations, the most significant being the absence of a control group.
Such an ideal control group should have had similar demographics and immunological
Fig 4. Patient (a) and death-censored graft survival (b) within the first year after the diagnosis of acute AMR in the
“per-patient” analysis. The last episode was taken as reference in patients with more than one rejection episode. AMR:
antibody-mediated rejection.
https://doi.org/10.1371/journal.pone.0250829.g004
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baseline characteristics, and have developed only acute T-cell mediated rejection (TCMR)
without AMR or no acute rejection. Nevertheless, this adjustment was not feasible, since sensi-
tized recipients with DSA pre-transplant tend precisely to develop acute AMR rather than
TCMR. This is the reason why we opted to provide some information on the recent study by
Van Delden et al., which analyzed the entire KT population within the STCS prospective
cohort [26]. On the other hand, our analysis provides new and valuable data on the differential
impact of anti-rejection therapies in the setting of acute AMR. Another study limitation is the
modest sample size of patients with acute AMR (n = 65). Given the heterogeneity of therapies
used, the risk factors for infection identified in the present study would need to be confirmed
in larger cohorts. However in this regard our experience can actually be considered as one of
the largest series reported to date.
In conclusion, the data obtained from the ongoing nationwide cohort showed a wide hetero-
geneity in the immunosuppressive therapies used to treat acute AMR after KT. Response to
therapy at three months was overall good, with one-year graft and patient survival rates exceed-
ing 90%. However, infectious complications were common after acute AMR treatment. Our
findings suggest that such risk varied according to the therapeutic modality, with an increased
risk for plasmapheresis while a trend for a protective effect was observed for IVIg on bacterial
infection. Finally, our experience emphasizes the need for well-designed prospective controlled
studies in AMR among KT recipients in order to define optimal therapeutic regimens in terms





This study was conducted in the framework of the STCS. The authors thank all patients for
their willingness to participate in the STCS, the central and local data managers, as well as the
physicians, nurses and investigators and all the personnel who were involved in the study and
in the STCS.
The members of the Swiss Transplant Cohort Study are:
Patrizia Amico1, John-David Aubert2, Vanessa Banz3, Sonja Beckmann1, Guido Beldi3,
Christian Benden4, Isabelle Binet5, Pierre-Yves Bochud2, Sanda Branca1, Heiner Bucher1,
Thierry Carell3, Emmanuelle Catana2, Yves Chalandon6, Sabina de Geest1, Olivier de Rouge-
mont7, Michael Dickenmann1, Michel Duchosal2, Thomas Fehr7, Sylvie Ferrari-Lacraz6,
Christian Garzoni3, Paola Gasche Soccal6, Christophe Gaudet6, Déla Golshayan2, Karine
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